Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biofrontera Inc. filings document a Nasdaq-listed dermatology biopharmaceutical company focused on photodynamic therapy. The company’s Form 8-K reports cover financial results, preliminary revenue updates, clinical disclosures for Ameluz PDT programs, patent-related proceedings, and Nasdaq continued-listing compliance notices. Its registered securities include common stock under BFRI and warrants under BFRIW.
Proxy materials describe board elections, stockholder voting matters, equity incentive plan approvals, auditor ratification, and governance procedures. The filing record also reflects disclosure controls around non-GAAP financial measures, Regulation FD announcements, risk-related litigation and patent matters, and capital-structure items such as warrants and preferred stock purchase rights.
Biofrontera Inc. reported first‑quarter 2026 net product revenue of $10.1M, up 17.4% from the prior year, driven mainly by higher Ameluz unit volumes and a late‑2025 price increase. Despite this growth, the company recorded a net loss of $4.8M, slightly larger than in 2025.
Cash and cash equivalents were $6.3M as of March 31, 2026, with operating cash outflows of about $0.1M in the quarter. Management states that existing capital resources are not adequate for twelve months and discloses substantial doubt about continuing as a going concern without additional financing or improved profitability.
The quarter also reflects a new cost structure from the 2025 strategic transaction with the Biofrontera Group, which replaced a 25% transfer‑pricing model with a lower earnout tied to Ameluz sales. Separately, an International Trade Commission final determination on RhodoLED XL led to a $0.5M remediation charge and restrictions on importing and selling certain lamp components, though the company has appealed elements of the patent dispute and the orders are under Presidential Review.
Biofrontera Inc. reported solid Q1 2026 progress, with revenue of $10.1 million, up about 17% from $8.6 million a year earlier, driven by higher Ameluz unit volumes and a price increase. Gross margin improved sharply to roughly 80% from 62%, reflecting a new earnout structure after its 2025 strategic transaction.
Operating loss narrowed slightly to $4.3 million, while net loss was $4.8 million, or $0.41 per share, compared with $4.2 million, or $0.47 per share. Adjusted EBITDA improved to a loss of $3.6 million, and operating cash usage was only $70 thousand, leaving $6.3 million in cash as of March 31, 2026.
The company highlighted key pipeline and regulatory milestones, including FDA filing acceptance of an sNDA for Ameluz PDT in superficial basal cell carcinoma with a PDUFA target action date of September 28, 2026, positive Phase 3 data in actinic keratoses on additional body sites, positive Phase 2b acne results, and regaining compliance with the Nasdaq Minimum Bid Price Requirement.
Biofrontera Inc. has called a fully virtual 2026 annual stockholder meeting for June 11, 2026. Investors will vote on electing two Class II directors, amending and restating the 2021 Omnibus Incentive Plan, and ratifying CBIZ CPAs P.C. as independent auditor for 2026.
The equity plan proposal would lift the share limit from 3,750,000 to 8,750,000, supporting future stock-based awards. As of the April 21, 2026 record date, 12,007,558 common shares and 22,286 preferred shares were outstanding, together entitled to 16,750,083 votes voting as a single class.
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on photodynamic therapy for dermatology, led by its Ameluz drug used with RhodoLED lamps to treat actinic keratosis. A key milestone was an October 20, 2025 strategic transaction through which it acquired all U.S. rights to Ameluz and RhodoLED from the Biofrontera Group, shifting control of manufacturing, clinical development and regulatory assets to the company. Biofrontera is pursuing label expansions, including superficial basal cell carcinoma, moderate to severe acne, and actinic keratosis on the trunk and extremities, with an sBCC supplemental NDA accepted by the FDA and a PDUFA date of September 28, 2026. A new Ameluz formulation without propylene glycol, backed by a U.S. patent expiring in 2043, has been implemented in U.S. production. As of December 31, 2025, the company had 92 employees and no single customer represented more than 10% of receivables or revenue. The filing highlights substantial regulatory, reimbursement, manufacturing, intellectual property, financing and going-concern risks.
Biofrontera Inc. reported record fourth quarter 2025 results, highlighted by strong growth and a swing to profitability. Q4 revenues rose 36% to $17.1 million from $12.6 million, with gross margin expanding to 82.4% from 58.0%. Operating income reached $4.6 million and net income was $5.6 million, both reversing prior-year losses.
For full year 2025, revenue increased 12% to $41.7 million, while the net loss narrowed to $10.5 million from $17.7 million. Adjusted EBITDA improved to $4.9 million in Q4 versus a $(1.4) million loss a year earlier, though it remained negative at $(10.6) million for the year. Cash and cash equivalents were $6.4 million as of December 31, 2025.
The company completed the purchase of all U.S. Ameluz and RhodoLED assets, reducing the earnout rate on U.S. net sales from 25%–35% to 12%–15%, and advanced its PDT pipeline with positive Phase 2b and Phase 3 data and an FDA-accepted sBCC sNDA with a PDUFA date in September 2026.
Biofrontera Inc. reported positive Phase 2b clinical results for its Ameluz® photodynamic therapy in moderate to severe acne vulgaris. In the 3-hour incubation per-protocol group, Ameluz achieved a 57.97% reduction in inflammatory lesions versus 36.51% with vehicle, and 25% of Ameluz patients met the mIGA co-primary endpoint compared with 21.4% on vehicle.
The 3-hour regimen also showed larger absolute reductions in inflammatory, non-inflammatory and total lesion counts and a safety profile consistent with prior PDT experience, with mainly mild to moderate burning and itching. Patient satisfaction was high, and the company plans to present these Phase 2b data to the FDA in Q3 2026 to discuss potential next development steps.
Biofrontera Inc. director Kevin Daniel Weber reported receiving an employee stock option grant to acquire 20,000 shares of the company’s stock. The option carries an exercise price of $0.00 per share and represents a new award, bringing his total directly held derivative securities from this grant to 20,000 options.
According to the disclosure, the option vests in twelve equal monthly installments beginning on April 4, 2026, meaning the right to exercise will phase in over one year. The filing notes that other options with different terms are not included in this reported transaction.
Biofrontera Inc. CEO and Chairman Hermann Luebbert reported several equity awards and an option-related share conversion. On March 4, 2026, he received 125,000 restricted stock units and an employee stock option for 125,000 shares, both at a price of $0.00 per unit or option. The restricted stock units vest in two equal yearly installments beginning on March 4, 2027, and may be settled in shares, cash, or a combination within 60 days of each vesting date. The option vests in two equal installments on September 4, 2026 and March 4, 2027. On March 5, 2026, 137,500 restricted stock units were exercised or converted into 137,500 shares of common stock at $0.00 per share, bringing his directly held common stock to 290,211 shares after the transaction.
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler reported equity compensation activity, mainly awards and a derivative conversion. On March 4, 2026, he received 62,500 restricted stock units and 62,500 employee stock options, both granted for no cash consideration.
On March 5, 2026, 87,500 restricted stock units were converted into 87,500 shares of common stock at a price of $0.00 per share, leaving him with 175,000 common shares held directly after the transaction.
Lanckriet Heikki reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Heikki Lanckriet received a grant of employee stock options covering 20,000 shares on March 4, 2026. These options were awarded at a stated price of $0.0000 per share and represent a new direct derivative holding of 20,000 options.
The option grant vests in twelve equal monthly installments, beginning on April 4, 2026, spreading the benefit to the director over one year. The disclosure notes that options with different terms are not included in this reported amount.